{"id":"abt","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL4761843","moleculeType":"Unknown","molecularWeight":"704.93"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Abatacept is a selective, high-affinity inhibitor of the CD80/CD86-CD28 interaction. By blocking this interaction, abatacept reduces the activation of T cells, which are a key component of the immune system. This action helps to decrease the severity of autoimmune diseases such as rheumatoid arthritis.","oneSentence":"Abatacept works by inhibiting T-cell activation through the CD80/CD86-CD28 costimulatory pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:05.436Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe rheumatoid arthritis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT05600894","phase":"PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts","enrollment":132},{"nctId":"NCT06514261","phase":"PHASE1","title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-18","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT06311227","phase":"PHASE2","title":"Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-16","conditions":"Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant","enrollment":20},{"nctId":"NCT06317649","phase":"PHASE2","title":"Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-27","conditions":"Acute Myeloid Leukemia","enrollment":147},{"nctId":"NCT06917911","phase":"PHASE2","title":"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-18","conditions":"Core Binding Factor Acute Myeloid Leukemia","enrollment":162},{"nctId":"NCT04840602","phase":"PHASE2","title":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-01-05","conditions":"Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia","enrollment":92},{"nctId":"NCT06802523","phase":"PHASE1","title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-21","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT05554393","phase":"PHASE2","title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-13","conditions":"Acute Myeloid Leukemia","enrollment":153},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT01366144","phase":"PHASE1","title":"Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma","enrollment":94},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT03289910","phase":"PHASE2","title":"Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-24","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia","enrollment":25},{"nctId":"NCT02152982","phase":"PHASE2, PHASE3","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-15","conditions":"Glioblastoma, Gliosarcoma","enrollment":447},{"nctId":"NCT03701282","phase":"PHASE3","title":"Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":720},{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT06672146","phase":"PHASE2","title":"Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-16","conditions":"Acute Myeloid Leukemia","enrollment":93},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT04269902","phase":"PHASE3","title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-02","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":247},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":120},{"nctId":"NCT00740805","phase":"PHASE1","title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-18","conditions":"Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Neoplasm","enrollment":81},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT03737981","phase":"PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":465},{"nctId":"NCT07437950","phase":"PHASE2","title":"Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-14","conditions":"Acute Myeloid Leukemia","enrollment":126},{"nctId":"NCT01351909","phase":"PHASE1","title":"Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-02","conditions":"Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":35},{"nctId":"NCT03581292","phase":"PHASE2","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-06","conditions":"Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma","enrollment":38},{"nctId":"NCT01434316","phase":"PHASE1","title":"Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-11","conditions":"Advanced Malignant Solid Neoplasm","enrollment":121},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":"Recurrent AL Amyloidosis, Refractory AL Amyloidosis","enrollment":24},{"nctId":"NCT07153497","phase":"PHASE2","title":"Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":132},{"nctId":"NCT03041688","phase":"PHASE1","title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-08","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":58},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT06656364","phase":"NA","title":"Esprit BTK Post-Approval Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2024-10-21","conditions":"Chronic Limb-Threatening Ischemia","enrollment":200},{"nctId":"NCT03874052","phase":"PHASE1","title":"Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Jennifer Saultz","startDate":"2019-08-16","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia","enrollment":51},{"nctId":"NCT04433520","phase":"","title":"Trevisio Post-Approval Study","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2020-09-14","conditions":"PFO - Patent Foramen Ovale, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect","enrollment":254},{"nctId":"NCT06423430","phase":"NA","title":"Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)","status":"RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2024-09-11","conditions":"Treatment Resistant Depression","enrollment":100},{"nctId":"NCT07218510","phase":"PHASE2","title":"Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-07","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":33},{"nctId":"NCT06763341","phase":"PHASE1","title":"A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-07-30","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":12},{"nctId":"NCT07133997","phase":"PHASE1","title":"Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-06-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":26},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":123},{"nctId":"NCT03504644","phase":"PHASE1, PHASE2","title":"Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-08-13","conditions":"Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma","enrollment":40},{"nctId":"NCT05423379","phase":"","title":"XIENCE Skypoint Large Vessel Post Approval Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2022-09-14","conditions":"Coronary Artery Disease","enrollment":102},{"nctId":"NCT05009095","phase":"NA","title":"The Listening Program® With Bone Conduction Headphones Changes Hypersensitivity to Sound and Behavioral Responses","status":"COMPLETED","sponsor":"Children's Health","startDate":"2022-06-13","conditions":"Autism Spectrum Disorder","enrollment":8},{"nctId":"NCT04872790","phase":"PHASE1","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-09-02","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia","enrollment":20},{"nctId":"NCT05750966","phase":"NA","title":"Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-07-19","conditions":"Cholangitis","enrollment":440},{"nctId":"NCT04285268","phase":"PHASE2","title":"Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-05-06","conditions":"High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT07228273","phase":"PHASE2","title":"Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":102},{"nctId":"NCT06922825","phase":"EARLY_PHASE1","title":"Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients","status":"WITHDRAWN","sponsor":"Eben Rosenthal","startDate":"2027-01","conditions":"Solid Tumor Cancer, Solid Tumor Malignancy, Cancer","enrollment":""},{"nctId":"NCT03222609","phase":"PHASE2","title":"A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-31","conditions":"Myelofibrosis (MF)","enrollment":191},{"nctId":"NCT07323641","phase":"PHASE2","title":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-02-01","conditions":"Lung Non-Small Cell Carcinoma","enrollment":60},{"nctId":"NCT04227899","phase":"NA","title":"LIFE-BTK Randomized Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2020-08-18","conditions":"Critical Limb Ischemia (CLI)","enrollment":261},{"nctId":"NCT01251874","phase":"PHASE1","title":"Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-22","conditions":"Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7","enrollment":44},{"nctId":"NCT01139970","phase":"PHASE1","title":"Veliparib and Temozolomide in Treating Patients With Acute Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06-04","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":66},{"nctId":"NCT04817241","phase":"PHASE1, PHASE2","title":"Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-10","conditions":"Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT01638546","phase":"PHASE2","title":"Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-27","conditions":"Recurrent Lung Small Cell Carcinoma","enrollment":97},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT01012817","phase":"PHASE1, PHASE2","title":"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11-03","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":88},{"nctId":"NCT01149083","phase":"PHASE2","title":"Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06-30","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma","enrollment":77},{"nctId":"NCT06357182","phase":"PHASE1","title":"Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-08-22","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT07096401","phase":"NA","title":"Efficacy of Aligners vs ABT and RCOS for Deep Bite Correction: CBCT Study","status":"NOT_YET_RECRUITING","sponsor":"Al-Azhar University","startDate":"2025-10-01","conditions":"Deep Bite Malocclusion","enrollment":27},{"nctId":"NCT02321514","phase":"NA","title":"Expanded Clinical Study of the Tendyne Mitral Valve System","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2014-11","conditions":"Mitral Valve Regurgitation","enrollment":191},{"nctId":"NCT04573660","phase":"","title":"Abbott Vascular Medical Device Registry","status":"RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2020-10-25","conditions":"Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions","enrollment":3784},{"nctId":"NCT07027878","phase":"","title":"JETi Lower Extremity Venous Thrombosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2020-03-06","conditions":"Venous Thrombosis","enrollment":121},{"nctId":"NCT06292936","phase":"NA","title":"RemI for Post-Bariatric Surgery Weight Regain","status":"RECRUITING","sponsor":"Temple University","startDate":"2024-04-15","conditions":"Obesity, Bariatric Surgery Candidate","enrollment":200},{"nctId":"NCT04370691","phase":"","title":"JETi Lower Extremity Arterial Thrombosis","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2020-03-06","conditions":"Arterial Thrombosis","enrollment":129},{"nctId":"NCT02595905","phase":"PHASE2","title":"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-15","conditions":"Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":344},{"nctId":"NCT00576654","phase":"PHASE1","title":"Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma","enrollment":73},{"nctId":"NCT00588991","phase":"PHASE1","title":"Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-04","conditions":"Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia","enrollment":12},{"nctId":"NCT04277442","phase":"PHASE1","title":"Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT01585805","phase":"PHASE2","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-15","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":88},{"nctId":"NCT02631733","phase":"PHASE1","title":"Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-05-31","conditions":"Malignant Solid Neoplasm","enrollment":18},{"nctId":"NCT06808035","phase":"NA","title":"Understanding Perinatal Spinal Cord Injury","status":"ENROLLING_BY_INVITATION","sponsor":"University of Louisville","startDate":"2024-01-09","conditions":"Perinatal Spinal Cord Injury","enrollment":6},{"nctId":"NCT06773286","phase":"NA","title":"Combining Spinal Cord Transcutaneous Stimulation and Activity-based Training in Inpatient Rehabilitation to Facilitate Upper Limb Function of Individuals with Acute to Subacute Cervical Spinal Cord Injury","status":"RECRUITING","sponsor":"Kessler Foundation","startDate":"2024-04-08","conditions":"Spinal Cord Injury Cervical","enrollment":30},{"nctId":"NCT04119284","phase":"NA","title":"Safety Outcomes of Vertebral Body Tethering Technique","status":"TERMINATED","sponsor":"Nemours Children's Clinic","startDate":"2019-09-01","conditions":"Idiopathic Adolescent Scoliosis","enrollment":8},{"nctId":"NCT04282148","phase":"NA","title":"Abbott Next Generation Drug Eluting Stent 48mm Study","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2020-06-17","conditions":"Coronary Artery Disease","enrollment":107},{"nctId":"NCT03904147","phase":"NA","title":"TRILUMINATE Pivotal Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2019-08-21","conditions":"Tricuspid Regurgitation","enrollment":572},{"nctId":"NCT04873817","phase":"","title":"Real-World Outcomes Study on Subjects Treated With Radiofrequency Ablation","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2021-06-29","conditions":"Pain","enrollment":184},{"nctId":"NCT03884231","phase":"","title":"A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2019-04-10","conditions":"Movement Disorders, Parkinson Disease, Essential Tremor","enrollment":74},{"nctId":"NCT06689306","phase":"NA","title":"7E Model in Nursing Education","status":"NOT_YET_RECRUITING","sponsor":"Ataturk University","startDate":"2024-11-15","conditions":"Nursing Education, Nursing Care","enrollment":70},{"nctId":"NCT03261674","phase":"NA","title":"Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-06-28","conditions":"Insomnia, Traumatic Brain Injury","enrollment":110},{"nctId":"NCT02263209","phase":"NA","title":"Investigation to Determine Safety of Taperloc Stems With BioGuard Coating When Used in Cementless Total Hip Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zimmer Biomet","startDate":"2013-10","conditions":"Osteoarthritis of Hip","enrollment":50},{"nctId":"NCT03507777","phase":"NA","title":"ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2018-05-17","conditions":"Coronary Artery Disease, Coronary Stenosis, Atherosclerosis","enrollment":2487},{"nctId":"NCT04915924","phase":"NA","title":"Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2020-10-30","conditions":"Advanced Heart Failure","enrollment":358},{"nctId":"NCT04255394","phase":"","title":"Exceed ABT Acetabular Cup Cementless System","status":"COMPLETED","sponsor":"Zimmer Biomet","startDate":"2010-07-01","conditions":"Osteoarthritis, Rheumatoid Arthritis, Correction of Functional Deformity","enrollment":677},{"nctId":"NCT05069597","phase":"PHASE4","title":"Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-10-14","conditions":"Cystic Fibrosis, Chronic Pancreatitis","enrollment":30},{"nctId":"NCT05537662","phase":"NA","title":"External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)","status":"RECRUITING","sponsor":"Abbott Medical Devices","startDate":"2023-06-06","conditions":"Chronic Pain","enrollment":30},{"nctId":"NCT06472986","phase":"NA","title":"Activity-Based Therapy and Transcutaneous Spinal Cord Stimulation After Spinal Cord Injury (ABT-TCSCS)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-10-07","conditions":"Spinal Cord Injuries, Spinal Cord Injury Cervical","enrollment":24},{"nctId":"NCT04703855","phase":"NA","title":"Hong Kong and Taiwan HM3 PMS","status":"TERMINATED","sponsor":"Abbott Medical Devices","startDate":"2021-07-14","conditions":"Advanced Heart Failure","enrollment":3},{"nctId":"NCT04726059","phase":"NA","title":"Motor & Autonomic Concomitant Health Improvements With Neuromodulation & Exercise Training: An SCI RCT","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2022-07-22","conditions":"Spinal Cord Injuries, Neurogenic Bladder, Neurogenic Bowel","enrollment":12},{"nctId":"NCT06147973","phase":"NA","title":"An Acceptance-Based Healthy Lifestyle Intervention for Diverse Adolescents","status":"RECRUITING","sponsor":"Drexel University","startDate":"2024-02-14","conditions":"Overweight and Obesity","enrollment":148},{"nctId":"NCT04949828","phase":"","title":"Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-09-16","conditions":"Chronic Pancreatitis","enrollment":63},{"nctId":"NCT02549092","phase":"PHASE3","title":"A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-26","conditions":"Advanced Parkinson's Disease","enrollment":89},{"nctId":"NCT06030284","phase":"NA","title":"The True Efficacy of Burst Spinal Cord Stimulation in the Management of Intractable Low Back Pain (TRU-BURST)","status":"WITHDRAWN","sponsor":"Abbott Medical Devices","startDate":"2023-04-20","conditions":"Chronic Intractable Pain","enrollment":""},{"nctId":"NCT06108869","phase":"NA","title":"Improving Health and Wellbeing for People Diagnosed With Chronic Spontaneous Urticaria (CSU)","status":"SUSPENDED","sponsor":"Royal College of Surgeons, Ireland","startDate":"2022-06-01","conditions":"Chronic Spontaneous Urticaria","enrollment":100},{"nctId":"NCT05590000","phase":"NA","title":"Study of Gemini Rechargeable Spinal Cord Stimulation (SCS) System","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2022-09-20","conditions":"Chronic Pain","enrollment":25},{"nctId":"NCT04484831","phase":"NA","title":"A Trial to Test an Acceptance-based Therapy Program Among Adolescent Girls With Overweight/Obesity","status":"COMPLETED","sponsor":"University of Florida","startDate":"2020-07-21","conditions":"Weight Loss, Obesity, Overweight","enrollment":43},{"nctId":"NCT03284788","phase":"NA","title":"Wellness Achieved Through Changing Habits (The WATCH Study)","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-08-08","conditions":"Weight Loss, Obesity, Overweight","enrollment":17},{"nctId":"NCT03924947","phase":"PHASE4","title":"A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-10-23","conditions":"Cystic Fibrosis","enrollment":36},{"nctId":"NCT05659836","phase":"","title":"Spinal Cord Stimulation Trial to Permanent Prediction","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2021-05-27","conditions":"Chronic Pain","enrollment":28},{"nctId":"NCT02307331","phase":"NA","title":"RSA Study of Sirius Stem and Exceed Cup","status":"COMPLETED","sponsor":"Region Skane","startDate":"2014-03","conditions":"Osteoarthritis","enrollment":48}],"_emaApprovals":[],"_faersSignals":[{"count":78,"reaction":"FEBRILE NEUTROPENIA"},{"count":41,"reaction":"ANAEMIA"},{"count":37,"reaction":"NAUSEA"},{"count":28,"reaction":"DEHYDRATION"},{"count":25,"reaction":"VOMITING"},{"count":25,"reaction":"WHITE BLOOD CELL COUNT DECREASED"},{"count":24,"reaction":"PNEUMONIA"},{"count":22,"reaction":"NEUTROPHIL COUNT DECREASED"},{"count":21,"reaction":"FATIGUE"},{"count":19,"reaction":"DYSPNOEA"}],"_approvalHistory":[],"publicationCount":4779,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["albuvirtide","any antibiotic therapy"],"phase":"marketed","status":"active","brandName":"ABT","genericName":"ABT","companyName":"Shanghai Public Health Clinical Center","companyId":"shanghai-public-health-clinical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abatacept works by inhibiting T-cell activation through the CD80/CD86-CD28 costimulatory pathway. Used for Moderate to severe rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}